Abstract
Microparticles are circulating fragments derived from blebbing and shedding of cell membranes through several mechanisms that include activation, apoptosis and cell damage. In the past they were largely considered as unimportant cell “dust”, but more refined detection techniques have revealed large variations in their relative proportion and concentration in numerous disease states. Importantly, these conditions include the most prevalent causes of death and disability in our societies, namely cardiovascular, neoplastic, and inflammatory diseases. Microparticles carry procoagulant, proapoptotic and neoangiogenetic materials in the blood stream, and can also be viewed as a technique cells may adopt to rapidly modify their phenotype, independently from genetic signals. In this review, we focus on the role of these very small ( < 1 micron) particles, not only as mere markers of an underlying pathologic state, but also as primordial intercellular messengers and defense mechanism that every viable cell can exploit in distress conditions. In this view, we suggest that this old communication system could be the target of future high-tech interventions, with potential broad consequences.
Keywords: Microparticles, atherosclerosis, coagulation, inflammation, apoptosis, angiogenesis, endothelial dysfunction, atrial fibrillation, renal failure, diabetes mellitus
Current Vascular Pharmacology
Title: Microparticles in Health and Disease: Small Mediators, Large Role?
Volume: 9 Issue: 4
Author(s): Italo Porto, Giovanni Luigi De Maria, Luca Di Vito, Claudia Camaioni, Massimo Gustapane and Luigi Marzio Biasucci
Affiliation:
Keywords: Microparticles, atherosclerosis, coagulation, inflammation, apoptosis, angiogenesis, endothelial dysfunction, atrial fibrillation, renal failure, diabetes mellitus
Abstract: Microparticles are circulating fragments derived from blebbing and shedding of cell membranes through several mechanisms that include activation, apoptosis and cell damage. In the past they were largely considered as unimportant cell “dust”, but more refined detection techniques have revealed large variations in their relative proportion and concentration in numerous disease states. Importantly, these conditions include the most prevalent causes of death and disability in our societies, namely cardiovascular, neoplastic, and inflammatory diseases. Microparticles carry procoagulant, proapoptotic and neoangiogenetic materials in the blood stream, and can also be viewed as a technique cells may adopt to rapidly modify their phenotype, independently from genetic signals. In this review, we focus on the role of these very small ( < 1 micron) particles, not only as mere markers of an underlying pathologic state, but also as primordial intercellular messengers and defense mechanism that every viable cell can exploit in distress conditions. In this view, we suggest that this old communication system could be the target of future high-tech interventions, with potential broad consequences.
Export Options
About this article
Cite this article as:
Porto Italo, Luigi De Maria Giovanni, Di Vito Luca, Camaioni Claudia, Gustapane Massimo and Marzio Biasucci Luigi, Microparticles in Health and Disease: Small Mediators, Large Role?, Current Vascular Pharmacology 2011; 9 (4) . https://dx.doi.org/10.2174/157016111796197206
DOI https://dx.doi.org/10.2174/157016111796197206 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Imaging of Myocardial Inflammation: More Evidence Toward a Causative Role in Cardiovascular Disease
Current Radiopharmaceuticals Periostin as a Heterofunctional Regulator of Cardiac Development and Disease
Current Genomics The Biological and Clinical Activity of Anti-Malarial Drugs In Autoimmune Disorders
Current Rheumatology Reviews Nitrogen Biobank for Cardiovascular Research
Current Cardiology Reviews Cardiac Fat as New Diagnostic Tool and Potential Therapeutic Target for Obesity Management and Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Preventing and Treating Anthracycline-Related Cardiotoxicity in Survivors of Childhood Cancer
Current Cancer Therapy Reviews Aetiology, Diagnosis and Treatment of Hydrops Foetalis
Current Pediatric Reviews Hypocholesterolemia
Current Vascular Pharmacology Effect of a New Class of Compounds of the Group of Substituted 5R1, 6H2-1,3,4-thiadiazine-2-amines on the Inflammatory and Cytokine Response in Experimental Myocardial Infarction
Current Vascular Pharmacology Surrogates of Insulin Sensitivity and Indices of Cardiometabolic Profile in Obesity
Current Vascular Pharmacology Meet the Editorial Board:
Current Drug Targets Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
Current Pharmaceutical Design Cell Therapy for the Treatment of Chronic Ischemic Heart Disease
Current Pharmaceutical Design Current and Promising Therapies in Autosomal Recessive Ataxias
CNS & Neurological Disorders - Drug Targets Flavones as a Privileged Scaffold in Drug Discovery: Current Developments
Current Organic Synthesis Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Cardiosphere-derived Progenitor Cells for Myocardial Repair Following Myocardial Infarction
Current Pharmaceutical Design 5-Adenosine Monophosphate-Activated Protein Kinase and the Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Mechanical Circulatory Support in Children
Current Cardiology Reviews Class IV Antiarrhythmic Agents: New Compounds Using an Old Strategy
Current Pharmaceutical Design